» Articles » PMID: 31239240

Racial and Socioeconomic Disparities in Bladder Cancer Survival: Analysis of the California Cancer Registry

Overview
Publisher Elsevier
Specialties Oncology
Urology
Date 2019 Jun 27
PMID 31239240
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To examine the California Cancer Registry (CCR) for bladder cancer survival disparities based on race, socioeconomic status (SES), and insurance in California patients.

Patients And Methods: The CCR was queried for bladder cancer cases in California from 1988 to 2012. The primary outcome was disease-specific survival (DSS), defined as the time interval from date of diagnosis to date of death from bladder cancer. Survival analyses were performed to determine the prognostic significance of racial and socioeconomic factors.

Results: A total of 72,452 cases were included (74.5% men, 25.5% women). The median age was 72 years (range, 18-109 years). The racial distribution among the patients was 81% white, 3.8% black, 8.8% Hispanic, 5.2% Asian, and 1.2% from other races. In black patients, tumors presented more frequently with advanced stage and high grade. Medicaid patients tended to be younger and had more advanced-stage, higher-grade tumors compared to patients with Medicare or managed care (P < .0001). Kaplan-Meier analysis demonstrated significantly poorer 5-year DSS in black, low SES, and Medicaid patients (P < .0001). When controlling for stage, grade, age, and gender, multivariate analysis revealed that black race (DSS hazard ratio = 1.295; 95% confidence interval, 1.212-1.384), low SES (DSS hazard ratio = 1.325; 95% confidence interval, 1.259-1.395), and Medicaid insurance (DSS hazard ratio = 1.349; 95% confidence interval, 1.246-1.460) were independent prognostic factors (P < .0001).

Conclusion: An analysis of the CCR demonstrated that black race, low SES, and Medicaid insurance portend poorer DSS. These findings reflect a multifaceted socioeconomic and public health conundrum, and efforts to reduce inequalities should be pursued.

Citing Articles

Examining Patient Characteristics in Bladder Cancer Clinical Trials Involving Immunotherapy.

Ikhapoh I, Atairu U, Reich A, Mantia C, Wei X, Sekar R J Clin Med. 2025; 14(3).

PMID: 39941550 PMC: 11818695. DOI: 10.3390/jcm14030879.


Socioeconomic disparities in survival of patients with non-muscle invasive urothelial carcinoma.

Baralo B, Daniels P, McIntire C, Thirumaran R, Melson J, Paul A World J Urol. 2025; 43(1):120.

PMID: 39937268 PMC: 11821756. DOI: 10.1007/s00345-024-05422-2.


Mitochondrial reprogramming by activating OXPHOS via glutamine metabolism in African American patients with bladder cancer.

Kami Reddy K, Piyarathna D, Park J, Putluri V, Amara C, Kamal A JCI Insight. 2024; 9(17).

PMID: 39253977 PMC: 11385078. DOI: 10.1172/jci.insight.172336.


Impact of rural location on receipt of standard of care treatment and survival for locally advanced bladder cancer in Louisiana.

Escott M, Yi Y, Foret A, Li T, Hsieh M, Delacroix Jr S Cancer Med. 2024; 13(12):e7301.

PMID: 38923853 PMC: 11199337. DOI: 10.1002/cam4.7301.


Racial Differences in the Detection Rate of Bladder Cancer Using Blue Light Cystoscopy: Insights from a Multicenter Registry.

Ladi-Seyedian S, Ghoreifi A, Konety B, Pohar K, Holzbeierlein J, Taylor J Cancers (Basel). 2024; 16(7).

PMID: 38610946 PMC: 11011163. DOI: 10.3390/cancers16071268.


References
1.
Prout Jr G, Wesley M, Greenberg R, Chen V, Brown C, Miller A . Bladder cancer: race differences in extent of disease at diagnosis. Cancer. 2000; 89(6):1349-58. DOI: 10.1002/1097-0142(20000915)89:6<1349::aid-cncr20>3.0.co;2-d. View

2.
Miller K, Siegel R, Lin C, Mariotto A, Kramer J, Rowland J . Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016; 66(4):271-89. DOI: 10.3322/caac.21349. View

3.
Williams S, Huo J, Chamie K, Hu J, Giordano S, Hoffman K . Underutilization of Radical Cystectomy Among Patients Diagnosed with Clinical Stage T2 Muscle-invasive Bladder Cancer. Eur Urol Focus. 2017; 3(2-3):258-264. DOI: 10.1016/j.euf.2016.04.008. View

4.
Ward E, Halpern M, Schrag N, Cokkinides V, DeSantis C, Bandi P . Association of insurance with cancer care utilization and outcomes. CA Cancer J Clin. 2007; 58(1):9-31. DOI: 10.3322/CA.2007.0011. View

5.
Bachman A, Parker A, Shaw M, Cross B, Stratton K, Cookson M . Minimally Invasive Versus Open Approach for Cystectomy: Trends in the Utilization and Demographic or Clinical Predictors Using the National Cancer Database. Urology. 2017; 103:99-105. DOI: 10.1016/j.urology.2017.02.018. View